Strategy for Pharmaceutical Industry in the Era of Artificial Intelligence
In the rapidly evolving biopharma industry, traditional launch models may no longer be effective due to the speed of change and advances in technology in the increasingly connected healthcare ecosystem. However, AI is making it easier for brands to put patients at the center and individualize their care, leading to a new era of launch excellence.
Pharmaceutical leaders are rethinking their portfolio management strategies due to the hypercompetitive environment and accelerated development timelines. The industry is experiencing a high number of targeted therapies in late-stage development across various therapeutic categories. This shift is causing a resurgence of small molecules and the emergence of more nimble biotech companies, driven by unpredictable M&A activity and enhanced technical capabilities.
Newly founded companies in the biopharma sector are using AI technology to optimize product launch strategies and planning. RedHill Biopharma, for instance, has shown operational improvements and strategic licensing deals, though explicit AI use in launch planning is not detailed. Propanc Biopharma is notable for integrating cryptocurrency assets, but not explicitly for AI-driven launch strategies. Despite this, no direct references to newly founded biopharma firms specifically employing AI for product launch optimization were found in the provided search results.
To succeed in this new era, brand teams need to find new ways to accelerate product adoption to drive sustainable revenues. They no longer have the luxury of taking five years to reach peak sales. By reinventing the traditional ROI model, considering how AI can help predict launch performance relative to pre-launch investment scenarios, brands can remove product and market infrastructure barriers and ensure optimal uptake in the context of the product, competition, and market development.
Investing in data and AI infrastructure where it matters most is crucial to integrate data across siloed departments, driving better insights and improved alignment across teams. This integration can lead to more efficient and effective planning, allowing teams to pivot from static planning to dynamic orchestration, from mass messaging to micro-targeting, and from siloed functions to agile, AI-augmented teams.
The larger healthcare ecosystem has become increasingly complex, and leaders are seeking new ways to drive efficiency and value through technology. The future of launch excellence is data-driven, dynamic, and decisively different, led by those who embrace technology, efficiency, and ecosystem-centricity at the core. Success in this new era will belong to those who can pivot from static planning to dynamic orchestration, from mass messaging to micro-targeting, and from siloed functions to agile, AI-augmented teams.
This article was originally published in Pharmaceutical Executive, with contributions from Karla Anderson and Cavay Ip. By 2030, 180 major drug patents are expected to expire, leading to a potential loss of $236 billion in revenue for pharmaceutical leaders. Embracing AI and adapting to the changing landscape is essential for success in the biopharma industry.
